Hong Kong stock market anomaly | Tianchen Biological-B (01779.HK) rose more than 6% LP-003 achieved the main endpoint in Phase III clinical trial for seasonal allergic rhinitis adaptogenic syndromes.

According to the Finance Channel App, Tianchen Biotech-B (01779.HK) has risen by over 6%, as of the time of publication, it has increased by 6.56%, reaching HK$161, with a trading volume of HK$22.9196 million.